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That the mind can influence the body during health and
disease is an ancient notion which, in part because of its or-
igins in anecdotal observations, has been an often and
sometimes hotly debated concept. Over 20 years ago, Dr.
Robert A. Good formulated a concise and elegant descrip-
tion of the problem as viewed from an immunological per-
spective. To quote Dr. Good:
“Immunologists are often asked whether the state of
mind can influence the body’s defenses. Can positive atti-
tude, a constructive frame of mind, grief, depression, or
anxiety alter ability to resist infections, allergies, autoimmu-
nities, or even cancer? Such questions leave me with a feel-
ing of inadequacy because I know deep down that such in-
fluences exist, but I am unable to tell how they work, nor
can I in any scientific way prescribe how to harness these
influences, predict or control them. Thus they cannot usu-
ally be addressed in scientific perspective. In the face of this
inadequacy, most immunologists are naturally uneasy and
usually plead not to be bothered with such things” (1).
Today we have established that the phenomenon of cen-
tral nervous system (CNS) regulation of immune function
exists and, at least roughly, elucidated the how and why of
Dr. Good’s “influences.” Perhaps the first experimental ev-
idence that the mind can influence the immune system was
the demonstration by Metal’nikov and Chorine in 1926
that an immune response can be conditioned in a classic
Pavlovian fashion (2). The essential paradigm is to repeat-
edly pair administration of an immunoregulatory substance
as an unconditioned stimulus with an external stimulation,
which is the conditioned stimulus (i.e., in the case of Pav-
lov, a ringing bell). With sufficient association, the condi-
tioned stimulus alone is able to cause immunoregulation.
This finding, in various forms, has stood the test of time
with numerous replications beginning most recently in
1975 (for a review, see reference 3). Among many exam-
ples, other convincing evidence for the concept is found in
the numerous effects of stress on immune function (for a
review, see reference 4) and the observation that behavioral
characteristics can predict susceptibility to autoimmunity in
an animal model of multiple sclerosis (5). Collectively,
findings such as these leave little doubt that the mind is ca-
pable of influencing the immune system. The findings that
stimulation or ablation of various regions of the brain could
negatively, as well as positively, alter immune responses
strongly suggested that immunoregulatory moieties resided
in the CNS (for a review, see reference 6). This being the
case, how do they work? Arguably two observations set the
stage for unraveling the puzzle. First, it was established that
peripheral immune responses could alter the firing rate of
neurons in the CNS (7). Thus, information can flow not
only from the CNS to the immune system but also in the
opposite direction. Further, innervation of immune tissues
and organs provides a conduit for such information (for a
review, see reference 8). But how? This became clear with
the second observation that immune cells can produce
neuropeptides such as 
 
 
 
-endorphin and other neurotrans-
mitters and neurons can make cytokines such as IL-1 (9).
Furthermore, cells of the immune system and the CNS
each have receptors for both cytokines as well as neuropep-
tides and neurotransmitters. Thus, the two systems can
communicate in a bidirectional fashion as a result of “speak-
ing the same chemical language” in terms of a common set
of signal molecules and their receptors (10, 11). It has
long been our contention that among other functions, the
immune system serves as a sensory organ (12). A sixth
sense, if you will, that completes our ability to be cognizant
not only of things we can see, feel, taste, touch, and smell
but also those things we cannnot. These would include
bacteria, viruses, antigens, tumor cells, etc. Recognition of
such “noncognitive stimuli” by the immune system would
result in transmission of information to the CNS via the
aforementioned shared signal molecules to cause a physio-
logical response that is ultimately beneficial to the host and
detrimental to the infectious agent. An example of such
communication involving cytokines is the findings that
upon peritoneal infection with bacteria or their products
the constellation of changes such as fever that are associ-
ated with sickness behavior come about as a direct result of
immune cell–derived proinflammatory cytokines signaling
the CNS via the subdiaphragmatic vagus nerve (references
13 and 14; Fig. 1). An example involving a neuropeptide is
found in the demonstration that an antinociceptive system
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can be activated by inflammation. This apparently results
from the production of 
 
 
 
-endorphin by immune cells at
the site of inflammation. Such 
 
 
 
-endorphin in turn acts on
local sensory nerve fibers to cause analgesia (15).
Contrariwise, the CNS alerts the immune system to en-
vironmental changes using the shared neuropeptide, neu-
rotransmitter, and cytokine receptors on immune cells. An
example of this is the aforementioned effects of stress to
dampen immune function. This apparently occurs via the
effects of products of the hypothalamic pituitary adrenal
axis on immune cells. An impairment of this axis to appro-
priately respond to inflammatory stressors has been shown
to predispose an animal to autoimmune disease as a result of
lack of regulation of the immune system (16). Thus, we
have proceeded quite a way in understanding the hows and
whys of CNS regulation of immune function.
In this issue, Bernik et al. (17) are among the first to ful-
fill the final challenge in Dr. Good’s narrative by finding a
way to harness an influence of the brain over the immune
system. In earlier studies, this group, led by Kevin J.
Tracey, demonstrated that the neurotransmitter, acetyl-
choline (ACh), had the ability to inhibit LPS-induced hu-
man macrophage production of proinflammatory cyto-
kines (TNF, IL-16, and IL-6), but not an antiinflammatory
cytokine (IL-10; reference 18). This effect occurred
through an action of the neurotransmitter on nicotinic
ACh receptors that were previously known to reside on
macrophages and other cells of the immune system (for a
review, see reference 19). Parenthetically, mononuclear
leukocytes also express choline acetyl-transferase and syn-
thesize ACh (20, 21).
Endotoxin (or LPS) is a product of all gram-negative
bacteria, which can cause shock (hypotension) and ulti-
mately, death. This occurs as a result of LPS activation of
macrophages to release TNF, which is a principle mediator
of acute LPS-induced shock (18). Building on the afore-
mentioned ability of ACh to suppress macrophage TNF
production in vitro, the Tracey group tested whether stim-
ulation of efferent vagus nerve activity might inhibit the
systemic inflammatory response to endotoxin. The ratio-
nale for this being the well known fact that ACh is the
principle vagal neurotransmitter and that the vagus nerve is
distributed throughout the reticuloendothelial system.
Consequently, Lewis rats underwent cervical vagotomy or
a sham surgical procedure and efferent vagus nerve activity
was stimulated in vagotomized animals. Remarkably, com-
pared with sham-operated controls, electrical stimulation of
the efferent vagus nerve very markedly inhibited TNF lev-
els in serum and in the liver and almost totally blocked hy-
potension caused by a lethal intravenous dose of LPS. In-
terestingly, vagotomy without stimulation resulted in a
significant increase in TNF levels and shortened the time to
development of shock as compared with sham-operated
controls. This, of course, might be expected if tonic sup-
pression of the aforementioned responses by ACh was re-
moved as a result of vagotomy. These findings were the
first to demonstrate a previously unrecognized, parasympa-
thetic antiinflammatory pathway by which the CNS mod-
ulates systemic inflammatory responses. The Tracey group
termed this the “cholinergic antiinflammatory pathway”
(Fig. 1).
In this study (17), Bernik et al. have expanded and
markedly extended their work on the cholinergic antiin-
flammatory pathway with an experimental therapeutic.
This compound, CNI-1493, is a tetravalent guanylhydra-
zone molecule that inhibits systemic inflammation. CNI-
1493 is currently undergoing testing in Phase II clinical tri-
als for Crohn’s disease and in preclinical testing has been
shown to be protective in a number of models, including
endotoxic shock, acute respiratory distress syndrome, sep-
sis, pancreatitis, experimental allergic encephalitis, stroke,
rheumatoid arthritis, and dextran sulfate colitis (for a re-
view, see reference 22). Prior to the present report, the an-
tiinflammatory effect of CNI-1493 was assumed to be
through its known ability to inhibit the phosphorylation of
p38 mitogen-activated protein kinase (MAPK), which
plays a key role in regulation of proinflammatory cytokine
synthesis (22). However, while evaluating the activity of
CNI-1493 in cerebral ischemia the authors made an unex-
Figure 1. A scheme for a vagal immune circuit. (1) Bacteria, LPS, or
other noncognitive stimuli are recognized by cells of the immune system
and cause the production of inflammatory cytokines such as TNF. The
inflammatory cytokines: (2) stimulate the afferent vagus nerve causing
sickness behavior and fever; (3) and also act to cause hypotension and
shock. (4) CNI-1493 or electrical stimulation of the efferent vagus nerve
activates a cholinergic antiinflammatory pathway. (5) The resulting ACh
inhibits immune cell production of inflammatory cytokines and conse-
quently blocks shock and possibly afferent vagal stimulation. 
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pected observation. As expected, the compound when in-
jected intracerebroventricularly inhibited cerebral TNF
synthesis. Surprisingly, by an intracerebroventricular route
it also inhibited the systemic TNF response to LPS, which
was used as a control. CNI-1493 also directly stimulated
vagal nerve activity. These observations led this group to a
remarkable possibility. Could the systemic antiinflamma-
tory action of CNI-1493 actually be mediated by a central
activation of the cholinergic antiinflammatory pathway?
This is precisely the conclusion that is reached, and it is
based on quite persuasive results. First, CNI-1493 adminis-
tered intracerebroventricularly was 100,000-fold more ef-
fective in suppressing LPS-induced TNF release and shock
as compared with intravenous administration. Thus, doses
that are ineffective systemically are active when given cen-
trally. Second, surgical or chemical (using the ACh antago-
nist atropine) vagotomy ablated the effects of CNI-1493
on LPS-induced TNF synthesis and shock whether the
compound was given intracerebroventricular or intrave-
nous. Lastly, electrical stimulation of the intact vagus nerve
conferred protection against endotoxic shock and TNF re-
lease (Fig. 1).
These findings have some truly provocative implica-
tions. Perhaps the most profound is the possibility of de-
veloping new classes of systemic antiinflammatory agents
that act centrally. Prior studies implicating the CNS in
mediating certain antiinflammatory actions of 
 
 
 
-melano-
cyte–stimulating hormone (23) and salicylates (24) via a
sympathetic neural route suggest that there are pathways
in addition to the one herein described that might be ex-
ploited. CNI-1493 may well serve as a prototype for the
developments of such new drugs. The identification of
the CNS receptor(s) for CNI-1493, as well as the central
neural fiber tract(s) that mediate its action, will be impor-
tant first steps in this process. A particularly interesting fu-
ture question will be whether CNI-1493 inhibition of
inflammatory cytokine production will also cause a block-
ade of cytokine-mediated afferent vagal stimulation. If so,
the compound might ameliorate fever and sickness behav-
ior as well as shock (Fig. 1). It will also be important to
determine whether vagus nerve stimulation, which is a
clinically approved therapy for epilepsy and depression
(with minimal morbidity) (25), can alter proinflammatory
cytokines in humans. If so, this might represent another
modality for activation of the cholinergic antiinflamma-
tory pathway for the treatment of inflammatory diseases.
Bringing these ideas to fruition may now provide a means
for harnessing the possibly powerful influences of the
CNS over the immune system.
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